PCOS and peptides: GLP-1 evidence vs everything else

What the PCOS guideline actually says

Polycystic ovary syndrome is common, and it is more than an ovarian condition: it carries metabolic risk, cardiovascular risk, sleep apnoea, a very high prevalence of anxiety and depression, and higher risk in pregnancy. Those points come from the 2023 international evidence-based guideline, written by panels across 39 professional and consumer organisations in 71 countries, with 254 recommendations and practice points ¹. Its own verdict on the evidence base is sobering: better than five years earlier, but still generally of low to moderate quality, in a condition its authors call neglected ¹.

The guideline keeps its emphasis on healthy lifestyle, emotional wellbeing and quality of life, asks clinicians to be aware of weight stigma, and calls for evidence-based medical therapy and cheaper, safer fertility management ¹. That is the frame for peptides. The question is not whether a peptide can be found that touches some pathway in PCOS, but which ones have been tested in women with PCOS, for which outcomes, and how well.

Liraglutide: the densest PCOS evidence

Liraglutide High has the most PCOS-specific trial data of any peptide, a point a 2026 review of incretin drugs in PCOS makes directly ². A Danish double-blind trial randomised 72 women with PCOS who were overweight or insulin-resistant to liraglutide 1.8 mg a day or placebo for 26 weeks. Liraglutide cut weight by 5.2 kg more than placebo, improved the bleeding pattern (a measure of how regular cycles were), raised sex hormone-binding globulin by 7.4 nmol/L and lowered free testosterone slightly; nausea and constipation were more common ³. The same trial measured fat inside the body: liraglutide reduced liver fat by 44%, visceral fat by 18% and the prevalence of fatty liver disease by two-thirds ⁴.

At the weight-management dose, a US trial randomised 82 women with obesity and PCOS to liraglutide 3 mg or placebo for 32 weeks alongside lifestyle advice. Weight fell 5.7% against 1.4%, 25 of 44 women on liraglutide lost at least 5% against 5 of 23 on placebo, and the free androgen index fell; gastrointestinal side effects hit 58.2% against 18.5% ⁵. These are real effects, and modest ones: roughly the weight loss liraglutide produces in people without PCOS, over half a year.

Exenatide: cycles, ovulation and one pregnancy signal

Exenatide High, the oldest GLP-1 drug, was tested in PCOS early. In a 2008 trial, 60 overweight women with infrequent ovulation were randomised to metformin, exenatide or both for 24 weeks; the combination beat either alone on menstrual frequency, ovulation rate, androgen index and insulin sensitivity, and both exenatide arms lost more weight than metformin. Only 70% finished ⁶. A larger Chinese open-label trial randomised 176 overweight or obese women to exenatide or metformin for 12 weeks, then put everyone on metformin. Exenatide produced more weight loss (4.3 against 2.3 kg) and better cycle frequency, and over the following 12 weeks natural pregnancy occurred in 43.6% of the exenatide group against 18.7% ⁷.

That pregnancy figure is striking and fragile: one open-label trial, measured after the drug was stopped. A 2021 trial of 119 women with obesity compared weekly exenatide, dapagliflozin, the two together, dapagliflozin with metformin, and phentermine-topiramate; the exenatide-dapagliflozin pair gave the best combination of weight and metabolic benefit, and every drug lowered testosterone and the androgen index ⁸.

Semaglutide and tirzepatide: big drugs, thin PCOS data

Semaglutide High and tirzepatide High are the drugs most people ask about, and their PCOS-specific evidence is the thinnest. In Slovenia, 25 women with obesity and PCOS took semaglutide 1 mg weekly with metformin for 16 weeks; median weight fell from 101 to 92 kg. Two years after stopping semaglutide, still on metformin, it was 95 kg: about a third of the loss had returned, and the cholesterol and glucose improvements had drifted back toward baseline, though 21 of 25 still weighed less than at the start ⁹. The same group's 16-week randomised study in 30 women was about taste: semaglutide improved taste recognition and changed brain responses to food cues ¹⁰.

For tirzepatide, the 2026 evidence map concluded there was no PCOS-specific evidence and that it could not be recommended beyond extrapolation from obesity and diabetes trials ². A trial published a month later starts to fill that gap: in an open-label Chinese study, 60 overweight or obese women were randomised to metformin alone or metformin plus tirzepatide 5 mg weekly for 16 weeks. The combination cut weight by 10.4 kg against 1.7 kg and visceral fat far more, with more cycle recovery and a higher pregnancy rate after a required eight weeks of barrier contraception ¹¹. It is a single small, unblinded trial, and it used a low dose.

What the pooled evidence shows

Meta-analyses put the individual trials in proportion. A 2026 review of 18 randomised trials comparing GLP-1 drugs with placebo, metformin or standard care found BMI lower by 1.09 kg/m² and insulin resistance improved, both with moderate certainty, but no significant effect on total testosterone, with very low certainty ¹². A 2023 network meta-analysis of drugs for infertility in PCOS ranked clomiphene plus exenatide among the options that raised clinical pregnancy, with moderate confidence, but found that none of the treatments clearly improved pregnancy in women with obesity ¹³.

The 2026 evidence map lists what is still missing for every GLP-1 drug in PCOS: reproductive outcomes, safety around conception and pregnancy, use in adolescents, long-term cardiovascular, kidney and metabolic effects, and which kinds of PCOS respond best. Its authors suggest the drugs are most rational for women with a high-risk metabolic form of PCOS, and argue that until PCOS-specific trials exist they should be seen as powerful but adjunctive weight-loss drugs, not treatments that modify the syndrome ².

Fertility, contraception and pregnancy: read the labels

Many women with PCOS are trying to conceive or trying not to, and two label sections matter more than any trial. The Wegovy label advises stopping semaglutide at least two months before a planned pregnancy because of its long half-life ¹⁴. The Zepbound label warns that tirzepatide can reduce the reliability of oral hormonal contraceptives: it advises switching to a non-oral method, or adding a barrier method, for four weeks after starting and for four weeks after each dose increase ¹⁵. The tirzepatide PCOS trial above built that caution into its design, requiring barrier contraception for eight weeks after the drug ¹¹.

The improvements in cycles and ovulation seen in the trials cut both ways. Weight loss and better ovulation can restore fertility, which is welcome for some women and an unplanned pregnancy for others, while still taking a drug whose pregnancy safety has not been established. Our article on peptides, GLP-1s, pregnancy and breastfeeding sets out each label's advice.

Kisspeptin: a research peptide with a real fertility use case

One peptide outside the GLP-1 class has serious fertility research behind it. Kisspeptin Medium is the hormone that switches on the reproductive axis. In IVF trials it has been tested as the trigger that matures eggs before collection: in the first trial in 53 women, a single injection matured eggs at every dose ¹⁶, and in a phase 2 trial in 60 women at high risk of ovarian hyperstimulation syndrome, it triggered egg maturation in 95%, with no moderate, severe or critical hyperstimulation ¹⁷. PubMed holds over 200 records pairing kisspeptin with PCOS, most of them physiology research into why ovulation fails ¹⁸. It remains an investigational peptide used in specialist fertility research, not something to buy.

Everything else: we counted

Clinics and sellers market a long list of research peptides for hormones, fat loss, inflammation or 'balance', often to women with PCOS. To see what evidence exists, we searched PubMed on October 3, 2026 for every record pairing PCOS with each compound, and for those indexed as randomised trials ¹⁸.

The pattern is stark. The GLP-1 drugs have dozens of records and a handful of randomised trials each; kisspeptin has a large physiology literature. For 10 of the 11 popular research peptides we checked, PubMed held not a single record mentioning PCOS, and none had a randomised trial ¹⁸. A count is a blunt tool, and a search can miss a paper, but it cannot miss a body of evidence. Anyone selling BPC-157, ipamorelin or a 'hormone-balancing' stack for PCOS is selling something that has never been studied in it.

The short version (as of October 3, 2026)

If a peptide is going to help with PCOS, the evidence points to the approved GLP-1 drugs, prescribed and monitored, as one part of care that also covers lifestyle, mental health and cardiometabolic risk ¹. Expect weight loss similar to what these drugs produce in anyone, with signals for cycles and androgens that are encouraging but come from small, short trials ^{12 2}. Plan contraception and pregnancy around the labels ^{14 15}. And treat any other peptide marketed for PCOS as untested, because it is.

Frequently asked questions

What is the best peptide for PCOS weight loss?

The GLP-1 drugs are the only peptides tested in randomised trials in PCOS. Liraglutide has the most PCOS-specific data; semaglutide and tirzepatide have much less, though both are strong weight-loss drugs.

Does semaglutide help PCOS?

PCOS-specific evidence is limited: a 16-week study in 25 women cut median weight from 101 to 92 kg, and about a third returned within two years of stopping. Larger PCOS trials are still needed.

Can GLP-1 drugs affect birth control or pregnancy?

Yes. The Wegovy label advises stopping semaglutide at least two months before a planned pregnancy, and the Zepbound label advises a non-oral or added barrier method for four weeks after starting tirzepatide and after each dose increase.

Are other peptides like BPC-157 studied for PCOS?

No. On October 3, 2026, PubMed held no record pairing PCOS with BPC-157, ipamorelin, CJC-1295, TB-500 or several other popular research peptides.

Related on Grey Peptides

• Women's health peptide hub
• Liraglutide
• Peptides, GLP-1s, pregnancy and breastfeeding

Sources

1. Teede, H. J., et al. (2023). Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Eur J Endocrinol, 189(2), G43-G64. PMID: 37580861
2. Jensterle, M., et al. (2026). Incretin-Based Anti-obesity Medications in Polycystic Ovary Syndrome: The Evidence Map. Drugs, 86(7), 1013-1032. PMID: 42106472
3. Nylander, M., et al. (2017). Effects of liraglutide on ovarian dysfunction in polycystic ovary syndrome: a randomized clinical trial. Reprod Biomed Online, 35(1), 121-127. PMID: 28479118
4. Frøssing, S., et al. (2018). Effect of liraglutide on ectopic fat in polycystic ovary syndrome: A randomized clinical trial. Diabetes Obes Metab, 20(1), 215-218. PMID: 28681988
5. Elkind-Hirsch, K. E., et al. (2022). Liraglutide 3 mg on weight, body composition, and hormonal and metabolic parameters in women with obesity and polycystic ovary syndrome: a randomized placebo-controlled-phase 3 study. Fertil Steril, 118(2), 371-381. PMID: 35710599
6. Elkind-Hirsch, K., et al. (2008). Comparison of single and combined treatment with exenatide and metformin on menstrual cyclicity in overweight women with polycystic ovary syndrome. J Clin Endocrinol Metab, 93(7), 2670-8. PMID: 18460557
7. Liu, X., et al. (2017). Efficacy of exenatide on weight loss, metabolic parameters and pregnancy in overweight/obese polycystic ovary syndrome. Clin Endocrinol (Oxf), 87(6), 767-774. PMID: 28834553
8. Elkind-Hirsch, K. E., et al. (2021). Exenatide, Dapagliflozin, or Phentermine/Topiramate Differentially Affect Metabolic Profiles in Polycystic Ovary Syndrome. J Clin Endocrinol Metab, 106(10), 3019-3033. PMID: 34097062
9. Jensterle, M., et al. (2024). The maintenance of long-term weight loss after semaglutide withdrawal in obese women with PCOS treated with metformin: a 2-year observational study. Front Endocrinol (Lausanne), 15, 1366940. PMID: 38665260
10. Jensterle, M., et al. (2025). Semaglutide and Taste in Women With Obesity and Polycystic Ovary Syndrome: A Randomized Placebo-Controlled Study. J Clin Endocrinol Metab, 111(1), e270-e280. PMID: 40341357
11. Yang, Z., et al. (2026). Short-Term Combined Treatment With Tirzepatide and Metformin for Overweight/Obese Chinese Women With Polycystic Ovary Syndrome: A Prospective, Open-Label, Randomised Controlled Trial. Diabetes Obes Metab, 28(8), 7380-7392. PMID: 42236268
12. Buragohain, S., et al. (2026). Effectiveness of GLP-1 Receptor Agonists in Patients With Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis of Randomised Controlled Trials. Cureus, 18(4), e106751. PMID: 42116999
13. Peng, G., et al. (2023). The effects of first-line pharmacological treatments for reproductive outcomes in infertile women with PCOS: a systematic review and network meta-analysis. Reprod Biol Endocrinol, 21(1), 24. PMID: 36869381
14. FDA. Wegovy (semaglutide) prescribing information, section 8.3 (DailyMed, effective June 18, 2026). Read October 3, 2026.
15. FDA. Zepbound (tirzepatide) prescribing information, section 7 (DailyMed, effective August 28, 2026). Read October 3, 2026.
16. Jayasena, C. N., et al. (2014). Kisspeptin-54 triggers egg maturation in women undergoing in vitro fertilization. J Clin Invest, 124(8), 3667-77. PMID: 25036713
17. Abbara, A., et al. (2015). Efficacy of Kisspeptin-54 to Trigger Oocyte Maturation in Women at High Risk of Ovarian Hyperstimulation Syndrome (OHSS) During In Vitro Fertilization (IVF) Therapy. J Clin Endocrinol Metab, 100(9), 3322-31. PMID: 26192876
18. Grey Peptides analysis: PubMed E-utilities counts of records and randomized controlled trials pairing PCOS with 16 compounds, run October 3, 2026; queries saved in _ops/phase2/research/pcos_pubmed_counts.json.

Educational information, not medical advice. Each dose in this guide names its source, an approved label or a published study. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose.